ArticleAdvances in laboratory medicine2025
Verification of fCAL turbo Buhlmann reagent for determining serum calprotectin.
Article in Advances in laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this study was to verify Buhlmann fCAL turbo reagent, used for analysing calprotectin in stool, on serum samples. Methods: Leftover patients' serum samples were used. Verification protocol included: precision performed in accordance with Clinical and Laboratory Standards Institute (CLSI) EP15-A3 guidelines; comparison of Buhlmann fCAL turbo and serum GCAL Gentian reagents; verification of reference intervals (RI) proposed from literature (0.68-5.45 mg/L) in accordance with CLSI EP28-A3C guidelines; limit of blank (LoB) and limit of quantitation (LoQ) performed in accordance with CLSI EP17-A2 guidelines; linearity performed in accordance with CLSI EP6-A guidelines; carry-over and lastly, hook effect. Acceptance criteria were based on manufacturer specifications stated in the package insert for the fCAL turbo Buhlmann reagent designed for analysing calprotectin in stool samples. Results: The CVs% for precision were within acceptance criteria, ≤10 %. Bland-Altman analysis showed the presence of a bias of 3.4 mg/L (95 % confidence interval 2.00-4.79). The equation for the Passing-Bablok regression was y= -0.01 (-0.08 to 0.06) + 0.37 (0.36-0.40)x, and it showed proportional difference. The obtained LoB was 0 mg/L, while the LoQ was 0.04 mg/L (CV% ≤ 20 %). The method was linear in the range 0.04-4.14 mg/L, and carry-over (0.1 %) and hook effect were not detected. The proposed RI in the literature was verified using 20 leftover patients' samples. Conclusions: Despite being declared for analysing stool samples only, Buhlmann fCAL turbo reagent can be used to determine serum calprotectin. Buhlmann fCAL turbo reagent is not comparable to the GCAL Gentian reagent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.